Application of a Forensic DNA Extraction System for Cannabis sativa Seed Identification.

Identification of Cannabis sativa seeds is crucial for law authorities fighting drug abuse and global trafficking. However, because they lack chemicals that are routinely used to pinpoint C. sativa plants, their identification becomes far more challenging. Germinating the seeds requires tremendous resources, is time consuming and is not effective when dealing with nonviable seeds. Botanical identification relies on well-trained experts. In recent years, laboratories have started to use specific DNA markers to achieve this goal. Real-time quantitative polymerase chain reaction (qPCR) was found to be a simple and efficient approach. However, seed DNA extraction is often labor intensive and involves many steps, which may also lead to DNA loss and contaminations. In the present study, we explored whether the PrepFiler™ Express Forensic DNA Extraction Kit, which is used in our DNA casework forensic laboratory, can reduce the work required for this critical step. We show that this kit has several advantages when compared with a dedicated plant extraction kit. In addition, we show that the combination of this extraction method and qPCR can enable high-throughput C. sativa seed identification.

Concordance testing between Powerplex ESI 16 Fast System and VeriFiler Express.

DNA profiles generated by different STR kits may show different alleles for identical amplified loci. This well-known phenomenon affects the smooth transition of data generated by new STR kits to a database or casework laboratory or cross-laboratory comparison of STR profiles. As in other DNA databases throughout the world, it has become clear that the number of the analyzed loci should be expanded for a variety of reasons, such as partial profiles resulting from low copy-number DNA template or degraded samples, working with mixtures or when prevalence of familial inbreeding. In the course of introducing a new STR kit, VeriFiler™ Express (Applied Biosystems, Foster City, CA, USA), we compared genotyping data of 1568 samples amplified by the VeriFiler™ Express with the data generated on the same samples by the Powerplex™ ESI FAST (Promega, Madison WI, USA) kit. Discordance was noted in 20 samples (1.27%), 14 (0.89%) of them showing allele dropout mismatch and six (0.38%) showing an additional fixed-size third allele. These rates are well above the reported rates of 0.4% for this kit. Since correct genotyping and accurate consistent allele assignment is of paramount importance, it seems timely to recommend for DNA laboratories and genetic-match search systems to take these possible inconsistencies into account.

tLivin displays flexibility by promoting alternative cell death mechanisms.

Livin is a member of the Inhibitor of Apoptosis (IAP) protein family that inhibits apoptosis triggered by a variety of stimuli. We previously demonstrated that while Livin inhibits caspase activity, caspases can cleave Livin to produce a truncated protein, tLivin and that this newly formed tLivin paradoxically induces cell death. However to date, the mechanism of tLivin-induced cell death is not fully understood. In this study, we set out to characterize the form of cell death mediated by tLivin. Here we demonstrate that, unlike most death-promoting proteins, tLivin is a flexible inducer of cell death capable of promoting necrosis or apoptosis in different cell lines. The unusual flexibility of tLivin is displayed by its ability to activate an alternative form of cell death when apoptosis is inhibited. Thus, tLivin can promote more than one form of cell death in the same cell type. Interestingly, in cells where tLivin induces necrosis, deletion of the caspase binding BIR domain results in tLivin-induced apoptosis, suggesting the BIR domain can potentially hamper the ability of tLivin to induce apoptosis. We further elucidate that tLivin activates the JNK pathway and both tLivin-induced apoptosis and necrosis are partially mediated by JNK activity. Acquired resistance to apoptosis, common in many tumors, impinges on the efficiency of conventional anti-cancer agents that function primarily by inducing apoptosis. The ability of tLivin to induce death of apoptosis-compromised cells makes it an attractive candidate for targeted cancer therapy.